A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors

Malignant Solid Tumors Clinical Trial

Official title:

A Phase Ib Study to Evaluate the Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Malignant Solid Tumors With TSC1/2 Genetic Alterations

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05508620
• Other study ID #: HB1901-003
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: October 2022
• Est. completion date: December 2024

Study information

• Verified date: August 2022
• Source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Contact: Zhehao Piao
• Phone: +86-024-81916392
• Email: pzpy[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, multi-center phase 1b study to evaluate the safety and efficacy of Sirolimus for injection (albumin-bound) in patients with malignant solid tumors with TSC1 or TSC2 genetic alterations.

Description:

This study will be conducted in two stages.

Stage 1: To evaluate the safety, tolerability and pharmacokinetics of Sirolimus for injection (albumin-bound), and determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). The Rolling-six design will be used for dose escalation.

Stage 2: To assess the antitumor activities of Sirolimus for injection (albumin-bound) in patients with malignant solid tumors harboring genetic alterations in TSC1 or TSC2.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 270
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed diagnosis of malignant solid tumors, with TSC1 or TSC2 genetic alterations, and have no standard treatment or have failed standard treatments.

• Patients must have archival tumor tissues or agreed to have a tumor biopsy (if not, the sponsor's consent is required for enrollment).

• At least 1 measurable lesion as defined by RECIST 1.1.

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.

• Life expectancy of =3 months.

• Adequate marrow and organ function.

• Fasting serum triglyceride must be <300 mg/dL or <3.42 mmol/L; fasting serum cholesterol must be<350 mg/dL or <9.07 mmol/L.

• Fasting blood glucose must be<6.1 mmol/L and HbA1c< 6.5% in dose escalation, in other stage must be < 7.8 mmol/L and be< 8% respectively.

• Women of child-bearing potential, or men whose partners are women of childbearing age must agree to use reliable contraceptive methods during the trial period and at least 6 months after the last administration; women of childbearing age must have a negative serum pregnancy test within 7 days prior to the first administration, should not be breast feeding.

• Patients should understand and willingness to sign a written informed consent form prior to study entry.

Exclusion Criteria:

• Prior treatment with an mTOR inhibitor.

• Anti-tumor treatment within 4 weeks prior to first dose of study treatment.

• Participation in another therapeutic clinical trial with 4 weeks before study treatment.

• Major surgery within 4 weeks prior to study treatment, or have not fully recovered from any previous procedure.

• Unresolved toxicity from prior anti-tumor therapy greater than Grade 1 as per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

• Patients with primary brain tumors or PEComa.

• Active uncontrolled or symptomatic central nervous system metastasis (CNS) or meningeal metastasis.

• History of serious cardiovascular disease.

• History of serious lung disease, such as interstitial lung disease and/or pneumonitis, or pulmonary hypertension, or pre-existing severely impaired lung function.

• Hydrothorax, ascites or pleural effusion with clinical symptoms or required treatment.

• Patients with hepatocellular carcinoma (HCC): Child-Pugh class B or C; or HCC with =50% liver occupation; or has a history or current evidence of hepatic encephalopathy; portal vein invasion at the main portal branch (Vp4).

• Live vaccine (including live attenuated vaccine) within 30 days before signing the informed consent.

• Infection that required systemic anti-infective therapy within 2 weeks before enrollment.

• History of autoimmune disease or immunodeficiency disease.

• Active Hepatitis B or Hepatitis C.

• Use of strong inhibitors or inducers of CYP3A4 within 2 weeks prior to start of treatment initiation, or requiring concomitant treatment during the study.

• Other server disease that may increase the risk of patients, or interfere the compliance of study procedures, or other reasons which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Related Conditions & MeSH terms

• Malignant Solid Tumors
• Neoplasms

Intervention

Drug:
• Sirolimus for Injection (Albumin-bound)
Intravenous infusion

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting toxicities (DLT)		At the end of Cycle 1 (each cycle is 21 days)
Primary	Recommended phase 2 dose (RP2D)		Up to 2 years
Primary	Overall response rate (ORR)		Up to 2 years
Secondary	Disease Control Rate (DCR)		Up to 2 years
Secondary	Duration of Response (DOR)		Up to 2 years
Secondary	Progression-free Survival (PFS)		Up to 2 years
Secondary	Overall survival (OS)		Up to 2 years
Secondary	Maximum Plasma Concentration (Cmax)		Up to18 weeks
Secondary	Time to reach maximum plasma concentration (Tmax)		Up to18 weeks
Secondary	Area Under the Curve (AUC)		Up to18 weeks